Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study

Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Takaaki, Hino, Masayuki, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, Sakaida, Emiko, Sekiguchi, Naohiro, Ono, Chiho, Aizawa, Mana, Tanetsugu, Yusuke, Koide, Yuichiro, Takahashi, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668794/
https://www.ncbi.nlm.nih.gov/pubmed/35963986
http://dx.doi.org/10.1007/s12185-022-03435-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668794/
https://www.ncbi.nlm.nih.gov/pubmed/35963986
http://dx.doi.org/10.1007/s12185-022-03435-4

Ejemplares similares